Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Clinical trial NCT05261490 · TERMINATED

Trial details

NCT number: NCT05261490
Sponsor: Pfizer
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer Ovarian Neoplasms Ovarian Carcinoma Fallopian Tube Cancer Epithelial Ovarian Cancer Primary Peritoneal Carcinoma

Start date: 2022-08-01
Primary completion: 2023-10-11
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.